AUSTIN, TX—Sheena Jonathan, co-founder and CEO of Natera, Inc. (NASDAQ:NTRA), reported sales of shares of the company’s common stock totaling approximately $909,125. The transactions, executed on January 2, 2025, were executed according to the trading plan of Rule 10b5-1. The sale comes as Natera’s shares are trading near a 52-week high of $175.63, after posting an impressive 180% return over the past year. According to InvestingPro analysis, the company maintains a GOOD financial health rating despite current market valuation concerns.
The sale included multiple transactions with prices ranging from $158.71 to $160.70 per share. Following these transactions, Jonathan retains direct ownership of 254,372 shares and indirect ownership of 44,782 shares through the Caraluna 1 and Caraluna 2 trusts.
These sales are part of a predetermined trading plan, which allows insiders to sell a predetermined number of shares at a specific time.
In other recent news, Natera Inc (NASDAQ:). has expanded its litigation against NeoGenomics (NASDAQ:), Inc. for patent infringement, by including an additional patent in a pending lawsuit. The company also reported record third-quarter revenue of $439.8 million, up 64% year-over-year, and performed 137,000 oncology tests, up 54% year-over-year. Analysts TD Cowen, Baird and Jefferies maintained their favorable ratings on Natera’s stock and raised their price targets, reflecting confidence in the company’s future performance.
In other cases, Natera amended the agreement with dr. Rabinowitz, executive chairman, to continue in her role subject to the terms of the agreement. However, the company faced a setback in its false advertising lawsuit Guardian of health (NASDAQ: ) but plans to ask the court to overturn the ruling. These recent developments provide investors with an insight into the current status of Natera.
This article was generated with the support of artificial intelligence and reviewed by an editor. See our T&C for more information.
